Claire L Price

Dr. Claire L Price

orcid

Research Focus & Metrics

Academic Career Length

13Years (2014-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
20 May 2015 in Pest Management Science
Verified
Journal Article
Closed access
PDF file
CPClaire L Price
Claire L Price
JPJosie Parker
Josie Parker
AWAndrew Gs Warrilow
Andrew Gs Warrilow
DKDiane E Kelly
Diane E Kelly
SKSteven L Kelly
Steven L Kelly

27 August 2014 in Journal of Chemical Biology
Verified
Journal Article
Closed access
PDF file
JPJosie Parker
Josie Parker
AWAndrew G. S. Warrilow
Andrew G. S. Warrilow
CPClaire L Price
Claire L Price
JMJonathan G. L. Mullins
Jonathan G. L. Mullins
DKDiane E. Kelly
Diane E. Kelly
SKSteven L. Kelly
Steven L. Kelly

5 June 2019 in Proceedings of the National Academy of Sciences
Verified
Journal Article
Closed access
PDF file
DLDavid C. Lamb
David C. Lamb
AFAlec Hoffman Follmer
Alec Hoffman Follmer
JGJared V. Goldstone
Jared V. Goldstone
DNDavid R. Nelson
David R. Nelson
AWAndrew G. Warrilow
Andrew G. Warrilow
JSJohn J Stegeman
John J Stegeman
Genes encoding cytochrome P450 (CYP; P450) enzymes occur widely in the Archaea, Bacteria, and Eukarya, where they play important roles in metabolism of endogenous regulatory molecules and exogenous chemicals. We now report that genes for multiple and unique P450s occur commonly in giant viruses in the Mimiviridae , Pandoraviridae , and other families in the proposed order Megavirales. P450 genes were also identified in a herpesvirus ( Ranid herpesvirus 3 ) and a phage ( Mycobacterium phage Adler). The Adler phage P450 was classified as CYP102L1, and the crystal structure of the open form was solved at 2.5 Å. Genes encoding known redox partners for P450s (cytochrome P450 reductase, ferredoxin and ferredoxin reductase, and flavodoxin and flavodoxin reductase) were not found in any viral genome so far described, implying that host redox partners may drive viral P450 activities. Giant virus P450 proteins share no more than 25% identity with the P450 gene products we identified in Acanthamoeba castellanii , an amoeba host for many giant viruses. Thus, the origin of the unique P450 genes in giant viruses remains unknown. If giant virus P450 genes were acquired from a host, we suggest it could have been from an as yet unknown and possibly ancient host. These studies expand the horizon in the evolution and diversity of the enormously important P450 superfamily. Determining the origin and function of P450s in giant viruses may help to discern the origin of the giant viruses themselves.

1 August 2016 in Antimicrobial Agents and Chemotherapy
Verified
Journal Article
Closed access
PDF file
AWAndrew G. S. Warrilow
Andrew G. S. Warrilow
JPJosie Parker
Josie Parker
CPClaire L Price
Claire L Price
WNW. David Nes
W. David Nes
EGEdward P. Garvey
Edward P. Garvey
SKSteven L. Kelly
Steven L. Kelly
Cryptococcosis is a life-threatening disease often associated with HIV infection. Three Cryptococcus species CYP51 enzymes were purified and catalyzed the 14α-demethylation of lanosterol, eburicol, and obtusifoliol. The investigational agent VT-1129 bound tightly to all three CYP51 proteins (dissociation constant [ K d ] range, 14 to 25 nM) with affinities similar to those of fluconazole, voriconazole, itraconazole, clotrimazole, and ketoconazole ( K d range, 4 to 52 nM), whereas VT-1129 bound weakly to human CYP51 ( K d , 4.53 μM). VT-1129 was as effective as conventional triazole antifungal drugs at inhibiting cryptococcal CYP51 activity (50% inhibitory concentration [IC 50 ] range, 0.14 to 0.20 μM), while it only weakly inhibited human CYP51 activity (IC 50 , ∼600 μM). Furthermore, VT-1129 weakly inhibited human CYP2C9, CYP2C19, and CYP3A4, suggesting a low drug-drug interaction potential. Finally, the cellular mode of action for VT-1129 was confirmed to be CYP51 inhibition, resulting in the depletion of ergosterol and ergosta-7-enol and the accumulation of eburicol, obtusifolione, and lanosterol/obtusifoliol in the cell membranes.

1 May 2019 in Antimicrobial Agents and Chemotherapy
Verified
Journal Article
Open access
PDF file
AWAndrew G. Warrilow
Andrew G. Warrilow
ANAndrew T. Nishimoto
Andrew T. Nishimoto
JPJosie Parker
Josie Parker
CPClaire L Price
Claire L Price
SFStephanie A. Flowers
Stephanie A. Flowers
SKSteven L. Kelly
Steven L. Kelly
Recombinant Candida albicans CYP51 (CaCYP51) proteins containing 23 single and 5 double amino acid substitutions found in clinical strains and the wild-type enzyme were expressed in Escherichia coli and purified by Ni 2+ -nitrilotriacetic acid agarose chromatography. Catalytic tolerance to azole antifungals was assessed by determination of the concentration causing 50% enzyme inhibition (IC 50 ) using CYP51 reconstitution assays.

1 December 2015 in Antimicrobial Agents and Chemotherapy
Verified
Journal Article
Closed access
PDF file
AWAndrew G. S. Warrilow
Andrew G. S. Warrilow
JPJosie Parker
Josie Parker
CPClaire L Price
Claire L Price
WNW. David Nes
W. David Nes
SKSteven L. Kelly
Steven L. Kelly
DKDiane E. Kelly
Diane E. Kelly
The incidence of triazole-resistantAspergillusinfections is increasing worldwide, often mediated through mutations in the CYP51A amino acid sequence. New classes of azole-based drugs are required to combat the increasing resistance to existing triazole therapeutics. In this study, a CYP51 reconstitution assay is described consisting of eburicol, purified recombinantAspergillus fumigatusCPR1 (AfCPR1), andEscherichia colimembrane suspensions containing recombinantA. fumigatusCYP51 proteins, allowingin vitroscreening of azole antifungals. Azole-CYP51 studies determining the 50% inhibitory concentration (IC50) showed thatA. fumigatusCYP51B (Af51B IC50, 0.50 μM) was 34-fold more susceptible to inhibition by fluconazole thanA. fumigatusCYP51A (Af51A IC50, 17 μM) and that Af51A and Af51B were equally susceptible to inhibition by voriconazole, itraconazole, and posaconazole (IC50s of 0.16 to 0.38 μM). Af51A-G54W and Af51A-M220K enzymes were 11- and 15-fold less susceptible to inhibition by itraconazole and 30- and 8-fold less susceptible to inhibition by posaconazole than wild-type Af51A, confirming the azole-resistant phenotype of these two Af51A mutations. Susceptibility to voriconazole of Af51A-G54W and Af51A-M220K was only marginally lower than that of wild-type Af51A. Susceptibility of Af51A-L98H to inhibition by voriconazole, itraconazole, and posaconazole was only marginally lower (less than 2-fold) than that of wild-type Af51A. However, Af51A-L98H retained 5 to 8% residual activity in the presence of 32 μM triazole, which could confer azole resistance inA. fumigatusstrains that harbor the Af51A-L98H mutation. The AfCPR1/Af51 assay system demonstrated the biochemical basis for the increased azole resistance ofA. fumigatusstrains harboring G54W, L98H, and M220K Af51A point mutations.